| abstract |
The invention takes advantage of the stimulation of non-AT1 receptors, especially AT2 and AT4 receptors, by AT1-receptor blockers or by AT2 or AT4 receptor selective agonists. The invention relates thus to the use of at least one angiotensin non-AT1 receptor-stimulating agent, for the preparation of a drug for brain ischemia complication prevention, especially stroke and cognitive decline prevention, and/or for acute stroke treatment. |